Roche has said it plans to UK price its latest multiple sclerosis drug Ocrevus in line with its close rival from Novartis - aiming to undercut some established rivals. Approved in Europe earlier ...

Credit: Genentech Ocrevus Zunovo is supplied in a single-dose vial containing 920mg of ocrelizumab and 23,000 units hyaluronidase per 23mL. Ocrevus Zunovo is a combination of ocrelizumab ...

When Roche's Genentech gained approval for Ocrevus in 2017, the first-in-class infused drug quickly became the best-selling treatment in a crowded multiple sclerosis (MS) market. Three years later ...

A subcutaneous (SC) injection version of Roche’s big-selling multiple sclerosis therapy Ocrevus has matched the current intravenous form in a clinical trial and, according to the company ...

Genentech, owned by Roche, has announced new clinical and real-world data for Ocrevus (ocrelizumab) for the treatment of patients with relapsing multiple sclerosis (RMS) or primary progressive ...

(RTTNews) - Swiss drug major Roche (RHHBY) announced Monday that the United States Food and Drug Administration has approved OCREVUS ZUNOVO (ocrelizumab & hyaluronidase-ocsq) for the treatment of ...

Swiss pharma giant Roche won approval from the Food and Drug Administration on Friday for an injectable version of its blockbuster multiple sclerosis therapy Ocrevus, cutting down the time needed ...

Roche said regulatory review of this drug is ongoing in additional markets. FDA approval of the MS drug, Ocrevus Zunovo, came the day after the cancer drug approval. Like infused Ocrevus ...